Obinutuzumab
- Generic Name
- Obinutuzumab
- Brand Names
- Gazyva, Gazyvaro
- Drug Type
- Biotech
- CAS Number
- 949142-50-1
- Unique Ingredient Identifier
- O43472U9X8
- Background
Obinutuzumab is a humanized monoclonal antibody used as a combination treatment with chlorambucil to treat patients with untreated chronic lymphocytic leukemia. It was approved by the FDA in November 2013 and is marketed under the brand name Gazyva. There is a black box warning of fatal Hepatitis B Virus (HBV) reactivation and fatal Progressive Multifocal Leukoencephalopathy (PML).
- Indication
Obinutuzumab is used as a combination treatment with chlorambucil to treat patients with untreated chronic lymphocytic leukemia.
- Associated Conditions
- Refractory Follicular Lymphoma, Previously untreated Chronic lymphocytic leukemia
Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy
- Conditions
- Relapsed Follicular LymphomaRefractory Follicular Lymphoma
- Interventions
- Drug: Investigation agent 2Drug: Investigation agent 3
- First Posted Date
- 2023-05-08
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- University of Birmingham
- Target Recruit Count
- 284
- Registration Number
- NCT05848765
- Locations
- 🇬🇧
Cardiff and vale University LHB, Cardiff, United Kingdom
🇬🇧Belfast Health & Social Care Trust, Belfast, United Kingdom
🇬🇧NHS Grampian, Aberdeen, United Kingdom
Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Marginal Zone Lymphoma
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2023-07-19
- Target Recruit Count
- 59
- Registration Number
- NCT05846750
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tian, China
Obinutuzumab in the Management of Idiopathic Membranous Nephropathy
- Conditions
- Idiopathic Membranous Nephropathy
- Interventions
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2023-05-10
- Lead Sponsor
- Qianfoshan Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT05845762
A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure.
- Conditions
- Mantle Cell LymphomaMantle Cell Lymphoma Refractory
- Interventions
- First Posted Date
- 2023-04-27
- Last Posted Date
- 2024-01-08
- Lead Sponsor
- Australasian Leukaemia and Lymphoma Group
- Target Recruit Count
- 42
- Registration Number
- NCT05833763
- Locations
- 🇦🇺
Peter MacCallum Cancer Centre, Parkville, Victoria, Australia
🇦🇺Sir Charles Gairdener, Nedlands, Western Australia, Australia
GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
- Conditions
- Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2023-04-04
- Last Posted Date
- 2023-04-04
- Lead Sponsor
- The First Affiliated Hospital of Soochow University
- Target Recruit Count
- 20
- Registration Number
- NCT05797948
- Locations
- 🇨🇳
the First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP
- Conditions
- Lymphoma, Large B-Cell, Diffuse
- Interventions
- First Posted Date
- 2023-04-04
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- Target Recruit Count
- 125
- Registration Number
- NCT05798156
- Locations
- 🇦🇹
Hanusch Krankenhaus, Wien, Austria
🇦🇹Kepler Universitätsklinikum, Linz, Austria
🇦🇹Ordensklinikum Linz - Barmherzige Schwestern, Linz, Austria
Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma
- Conditions
- Follicular LymphomaMarginal Zone LymphomaIndolent Non-hodgkin Lymphoma
- Interventions
- First Posted Date
- 2023-03-24
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- Reid Merryman, MD
- Target Recruit Count
- 50
- Registration Number
- NCT05783596
- Locations
- 🇺🇸
Mount Sinai Medical Center, New York, New York, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
A Phase 1 Study of SAIL66 in Patients With CLDN6-positive Locally Advanced or Metastatic Solid Tumors
- First Posted Date
- 2023-02-21
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Chugai Pharmaceutical
- Target Recruit Count
- 231
- Registration Number
- NCT05735366
- Locations
- 🇺🇸
Georgia Cancer Center at Augusta University, Augusta, Georgia, United States
🇺🇸MUSC Hollings Cancer Center, Charleston, South Carolina, United States
🇺🇸Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies
- Conditions
- DLBCLMarginal Zone LymphomaFollicular LymphomaB-cell LymphomaPrimary Mediastinal Large B Cell LymphomaNon Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2022-12-16
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Acepodia Biotech, Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT05653271
- Locations
- 🇺🇸
AdventHealth Orlando, Orlando, Florida, United States
🇺🇸Emory University, Atlanta, Georgia, United States
🇺🇸Indiana University Simon Comprehensive Cancer Center, Indianapolis, Indiana, United States
Zanubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leukemia (CLL) With Response-based Obinutuzumab
- Conditions
- Leukemia, Lymphocytic, Chronic, B-Cell
- Interventions
- First Posted Date
- 2022-12-14
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 50
- Registration Number
- NCT05650723
- Locations
- 🇺🇸
Weill Cornell Medicine/NewYork-Presberteryian Hospital, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.